0
ARTICLE |

The Purity of Cholestyramine Resin

Mark R. Goldstein, MD
JAMA. 1989;262(22):3127. doi:10.1001/jama.1989.03430220048010.
Text Size: A A A
Published online

To the Editor. —  The suit filed by Warner - Lambert Company, Morris Plains, NJ, on March 21, 1989, against chemical company Rohm & Haas, Philadelphia, Pa, has profound and far-reaching implications. It accuses Rohm & Haas of negligence, breach of contract, and wanton and reckless conduct (The Philadelphia Inquirer. March 23, 1989: 1-C, 13-C) regarding the sale of pesticide-contaminated cholestyramine resin. Two pharmaceutical companies in this country have used cholestyramine resin manufactured by Rohm & Haas for the manufacture of cholesterol-lowering drugs. Bristol-Myers US Pharmaceutical Group, Evansville, Ind, supplies cholestyramine resin in the form of a powder, Questran, and Warner-Lambert supplies cholestyramine resin in the form of a chewable bar, Cholybar. Questran has been available for approximately 20 years and Cholybar was released recently, in November 1988.In May 1988, Bristol-Myers, under an agreement with the Food and Drug Administration, recalled 200 million doses of Questran contaminated with pesticides (The Philadelphia

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs